Retinal Dystrophies Clinical Trials

10 recruitingLast updated: May 21, 2026

There are 10 actively recruiting retinal dystrophies clinical trials across 9 countries. Studies span Phase 1, Not Applicable, Phase 2. Top locations include Houston, Texas, United States, Jacksonville, Florida, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Retinal Dystrophies Trials at a Glance

10 actively recruiting trials for retinal dystrophies are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Houston, Jacksonville, and Ann Arbor. Lead sponsors running retinal dystrophies studies include PYC Therapeutics, Ray Therapeutics, Inc., and Institute of Molecular and Clinical Ophthalmology Basel.

Browse retinal dystrophies trials by phase

About Retinal Dystrophies Clinical Trials

Looking for clinical trials for Retinal Dystrophies? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Dystrophies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Dystrophies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

X-linked RetinoschisisRetinitis PigmentosaStargardt Disease+3 more
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting

VIsual Cerebral ConnecTivity On Functional Magnetic Resonance Imaging in Patients With Hereditary REtinal Dystrophies

Vision Functional Brain Networks in Patients With Hereditary Retinal Dystrophies
Fondation Ophtalmologique Adolphe de Rothschild200 enrolled1 locationNCT04648124
Recruiting

Natural History Study of Inherited Retinal Diseases

MutationMacular DegenerationRetinal Dystrophies+7 more
Zhongmou Therapeutics200 enrolled1 locationNCT07085533
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Not Applicable

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

Retinal Dystrophies
Duke University80 enrolled1 locationNCT06177977
Recruiting
Phase 1

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting

EyeConic: Qualification for Cone-Optogenetics

Retinal Dystrophies
Institute of Molecular and Clinical Ophthalmology Basel1,000 enrolled9 locationsNCT05294978
Recruiting
Phase 1

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Retinal DegenerationRetinal DiseaseEye Diseases+2 more
PYC Therapeutics12 enrolled5 locationsNCT06455826
Recruiting

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Retinitis PigmentosaStargardt DiseaseRetinal Dystrophies+4 more
Ray Therapeutics, Inc.120 enrolled1 locationNCT06375239
Recruiting

Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer

Retinitis PigmentosaGlaucomaRetinal Dystrophies
Sheba Medical Center200 enrolled1 locationNCT02014389